EP0528819A1 - GENES MODIFIES DU $i(BACILLUS THURINGIENSIS) CODANT UNE PROTEINE CRISTALLINE INSECTICIDE ET LEUR EXPRESSION DANS DES CELLULES DE PLANTES - Google Patents

GENES MODIFIES DU $i(BACILLUS THURINGIENSIS) CODANT UNE PROTEINE CRISTALLINE INSECTICIDE ET LEUR EXPRESSION DANS DES CELLULES DE PLANTES

Info

Publication number
EP0528819A1
EP0528819A1 EP91907836A EP91907836A EP0528819A1 EP 0528819 A1 EP0528819 A1 EP 0528819A1 EP 91907836 A EP91907836 A EP 91907836A EP 91907836 A EP91907836 A EP 91907836A EP 0528819 A1 EP0528819 A1 EP 0528819A1
Authority
EP
European Patent Office
Prior art keywords
gene
icp
plant
sequences
mrna
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
EP91907836A
Other languages
German (de)
English (en)
Inventor
Marc Cornelissen
Piet Soetaert
Maike Stam
Jan Dockx
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Bayer CropScience NV
Original Assignee
Plant Genetic Systems NV
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Plant Genetic Systems NV filed Critical Plant Genetic Systems NV
Publication of EP0528819A1 publication Critical patent/EP0528819A1/fr
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/32—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Bacillus (G)
    • C07K14/325—Bacillus thuringiensis crystal peptides, i.e. delta-endotoxins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/82—Vectors or expression systems specially adapted for eukaryotic hosts for plant cells, e.g. plant artificial chromosomes (PACs)
    • C12N15/8241—Phenotypically and genetically modified plants via recombinant DNA technology
    • C12N15/8261—Phenotypically and genetically modified plants via recombinant DNA technology with agronomic (input) traits, e.g. crop yield
    • C12N15/8271—Phenotypically and genetically modified plants via recombinant DNA technology with agronomic (input) traits, e.g. crop yield for stress resistance, e.g. heavy metal resistance
    • C12N15/8279—Phenotypically and genetically modified plants via recombinant DNA technology with agronomic (input) traits, e.g. crop yield for stress resistance, e.g. heavy metal resistance for biotic stress resistance, pathogen resistance, disease resistance
    • C12N15/8286—Phenotypically and genetically modified plants via recombinant DNA technology with agronomic (input) traits, e.g. crop yield for stress resistance, e.g. heavy metal resistance for biotic stress resistance, pathogen resistance, disease resistance for insect resistance
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A40/00—Adaptation technologies in agriculture, forestry, livestock or agroalimentary production
    • Y02A40/10—Adaptation technologies in agriculture, forestry, livestock or agroalimentary production in agriculture
    • Y02A40/146—Genetically Modified [GMO] plants, e.g. transgenic plants

Definitions

  • This invention provides a modified Bacillus thuringiensis (“Bt”) gene (the "modified BtlCP gene”) encoding all or an insecticidally-effective portion of a Bt insecticidal crystal protein (“ICP”) .
  • Bt Bacillus thuringiensis
  • ICP Bt insecticidal crystal protein
  • Plant genetic engineering technology has made significant progress during the last 10 years. It has become possible to introduce stably foreign genes into plants. This has provided exciting opportunities for modern agriculture.
  • Derivatives of the Ti-plasmid of the plant pathogen, Aqrobacterium tumefaciens have proven to be efficient and highly versatile vehicles for the introduction of foreign genes into plants and plant cells.
  • free DNA delivery methods such as electroporation, microinjection, pollen-mediated gene transfer and particle gun technology, have been developed for the same purpose.
  • Bt crystal spore preparations have been used as biological insecticides.
  • the commercial use of Bt sprays has however been limited by high production costs and the instability of crystal proteins when exposed in the field (Vaeck et al., 1987).
  • the heterogeneity of Bt strains has been well documented. Strains active against Lepidoptera (Dulmage et al., 1981), Diptera (Goldberg and Margalit, 1977) and Coleoptera (Krieg et al., 1983) have been described.
  • Bt strains produce endogenous crystals upon sporulation. Upon ingestion by insect larvae, the crystals are solubilized in the alkaline environment of the insect midgut giving rise to a protoxin which is subsequently proteolytically converted into a toxic core fragment or toxin of 60-70 kDa. The toxin causes cytolysis of the epithelial midgut cells.
  • the specificity of Bt ICPs can be determined by their interaction with high-affinity binding sites present on insects' midgut epithelia.
  • Bt ICPs The identification of Bt ICPs and the cloning and sequencing of Bt ICP genes has been reviewed by H ⁇ fte and Whiteley (1989) .
  • the Bt ICP genes share a number of common properties. They generally encode insecticidal proteins of 130 kDa to 140 kDa or of about 70 kDa, which contain toxic fragments of 60 ⁇ 10 kDa (Hofte and Whiteley, 1989) .
  • the Bt ICP genes have been classified into four major groups according to both their structural similarities and insecticidal spectra (H ⁇ fte and Whiteley, 1989) : Lepidoptera-specific (Cryl) , Lepidoptera- and Diptera-specific (Cryll) , Coleoptera- specific (Crylll) and Diptera-specific (Cry IV) genes.
  • the Lepidoptera-specific genes (Cryl) all encode 130-140 kDa proteins. These proteins are generally synthesized as protoxins. The toxic domain is localized in the N-terminal half of the protoxin. Deletion analysis of several Cryl genes confirm that 3' portions of the protoxins are not absolutely required for toxic activity (Schnepf et al., 1989).
  • Cry II genes encode 65 kDa proteins (Widner and Whiteley, 1985) .
  • the Cry II A proteins are toxic against both Lepidoptera and Diptera while the Cry II B proteins are toxic only to Lepidopteran insects.
  • the Coleoptera-specific genes generally encode proteins with a molecular weight of about 70 kDa. (Whiteley and H ⁇ fte, 1989) .
  • the corresponding gene (cry III A) expressed in E ⁇ coli directs the synthesis of a 72 kDa protein which is toxic for the Colorado potato beetle.
  • This 72 kDa protein is processed to a 66 kDa protein by spore- associated bacterial proteases which remove the first 57 N-terminal amino acids (Mc Pherson et al., 1988). Deletion analysis demonstrated that this type of gene cannot be truncated at its 3'-end without the loss of toxic activity (H ⁇ fte and Whiteley, 1989) . Recently, an anti-coleopteran strain, which produces a 130 kDa, protein has also been described (European patent application (“EPA”) 89400428.2).
  • the cry IV class of crystal protein genes is composed of a heterogenous group of Diptera-specific crystal protein genes (H ⁇ fte and Whiteley, 1989) .
  • Aqrobacterium-mediated gene transfer has been used to express chimaeric Bt ICP genes in plants (Vaeck et al., 1987; Barton et al., 1987; Fischoff et al., 1987).
  • Bt ICP genes were placed under the control of a strong promoter capable of directing gene expression in plant cells. It is however remarkable that expression levels in plant cells were high enough only to obtain insect-killing levels of Bt ICP genes when truncated genes were used (Vaeck et al. , 1987; Barton et al., 1987). None of the transgenic plants containing a full-length Bt ICP gene produced insect-killing activity. Moreover, Barton et al.
  • EP European patent publications
  • changes in codon usage can introduce cryptic regulatory signals in a gene, thereby causing problems in one or more of the six steps mentioned above for gene expression, and thus inhibiting or interfering with transcription and/or translation of the modified foreign gene in plant cells.
  • changes in codon usage can cause differential rates of mRNA production, producing instability in the mRNA, so produced (e.g., by exposure of regions of the mRNA, unprotected by ribosomes, to attack and degradation by cytoplasmic enzymes) .
  • Changes in codon usage also can inadvertantly cause inhibition or termination of RNA poly erase II elongation on the so-modified gene.
  • the adenine and thymine sequences are changed to cytosine and guanine sequences in translational codons of at least one region of the gene which, during transcription, would otherwise have thereon a relatively low percentage of RNA polymerase II as compared to another adjacent upstream (i.e., 5') region of the gene.
  • the modified Bt ICP gene resulting from the process.
  • a process for improving the resistance of a plant against insect pests by transforming the plant cell genome with at least one modified Bt ICP gene.
  • This invention also relates to a chimaeric gene that can be used to transform plant cells and that contains the following operably-1inked DNA fragments in the same transcriptional unit:
  • This invention further relates to:
  • - a cell of a plant the nuclear genome of which has been transformed to contain, preferably stably integrated therein, the modified Bt ICP gene, particularly the chimaeric gene; - cell cultures consisting of the plant cell;
  • Bt ICP should be understood as an intact protein or a part thereof which has insecticidal activity and which can be produced in nature by B. thuringiensis.
  • a Bt ICP can be a protoxin, as well as an active toxin or other insecticidal truncated part of a protoxin which need not be crystalline and which need not be a naturally occurring protein.
  • Bt ICP is a Bt2 insecticidal crystal protein (H ⁇ fte et al., 1986), as well as its insecticidally effective parts which are truncated at its C- and/or N-terminal ends towards its tryspsin cleavage site(s) and preferably having a molecular weight of 60-80 kDa.
  • Bt ICPs are: Bt2, Bt3, Bt4, Btl3, Btl4, Btl5, Btl8, Bt21, Bt22, Bt73, Bt208, Bt245, BtI260 and BtI109P as disclosed in PCT publications WO90/15139 and WO90/09445, in H ⁇ fte and Whiteley (1989) and in EPA 90403724.9.
  • protoxin should be understood as the primary translation product of a full-length gene encoding a Bt ICP.
  • toxin or "active toxin” or “toxic core” should all be understood as a part of a protoxin which can be obtained by protease (e.g., by trypsin) cleavage and has insecticidal activity.
  • truncated Bt gene should be understood as a fragment of a full-length Bt gene which still encodes at least the toxic part of the Bt ICP, preferentially the toxin.
  • modified Bt ICP gene should be understood as a DNA sequence which encodes a Bt ICP, and in which the content of adenine ("A") and thymine (“T”) has been changed to guanine ("G") and cytosine ("C") in codons, preferably at least 3, in at least one region of the DNA sequence without affecting the original amino acid sequence of the Bt ICP.
  • a and T content is changed to G and C in at least 3 codons.
  • the A-T content of at least about 10 codons, particularly at least about 33 codons be changed to G-C.
  • region of a modified Bt ICP gene is meant any sequence encoding at least three translational codons which affect expression of the gene in plants.
  • the run-on assay has been used to determine initially the relative efficiency of RNA polymerase II complexes to initiate transcription of Bt ICP genes and thereafter to determine the relative distribution and migration efficiency of the RNA polymerase II complexes on the Bt ICP genes.
  • N28 - 220 contains the bt884 fragment under control of the TR 2' promoter as a chimaeric gene.
  • Bt884 is a 5' fragment of the bt2 gene (H ⁇ fte et al., 1986) up to codon 610 (Vaeck et al., 1987).
  • isolated nuclei of N28 - 220 were incubated with highly labeled radioactive RNA precursors, so that the RNA transcripts being synthesized at the time became radioactively labeled. The RNA polymerase II molecules caught in the act of transcription in the cell continue elongating the same RNA molecules in vitro.
  • nuclear run-on assays of nuclei of N28 - 220 culture revealed that transcription from the TR1' and TR2' promoters is about equally efficient. This implies that the low Bt ICP (i.e., Bt884) expression levels are not due to a specifically reduced transcriptional activity of the TR2* promoter.
  • nuclear run-on analysis with N28 - 220 nuclei indicated that transcription elongation of the nascent Bt ICP mRNA is impaired somewhere between 700 to 1000 nucleotides downstream of the start of transcription.
  • RNA polymerase II is not able to transcribe the Bt ICP coding sequence with 100 % efficiency.
  • Filter binding assays using labeled Bt DNA fragments spanning this region and protein extract prepared from tobacco nuclei reveal that this DNA region undergoes specific interactions with proteins present in nuclei. These interactions are the prime candidates that cause or affect the impaired elongation of transcription by RNA polymerase II through this region.
  • Bt ICP expression levels will increase.
  • other mechanisms responsible for impaired elongation in this region cannot be excluded.
  • sequences within the coding region involved in negative control of cytoplasmic Bt ICP mRNA levels have been identified by deletion analysis.
  • 24 deletion derivatives of pVE36 have been constructed.
  • Three main types of deletion mutants have been constructed (see fig. 3) : - 5' end deletions
  • neo mRNA levels were measured in relation to cat mRNA levels in RNA extracts of SRI protoplasts.
  • the ratio between the neo and cat mRNA level was used to quantify on a relative basis the nptll transcript (i.e., mRNA) levels produced by the different constructions.
  • a 326 bp region (fig. 6b) was identified in the bt2 gene that is involved in the negative control of BT ICP expression and that is located between nucleotide position 674 and nucleotide position 1000, particularly a 268 bp region between nucleotide positions 733 and 1000, quite particularly a 29 bp region between nucleotide positions 765 and 794 which carries two perfect CCAAT boxes which are known to be able to cause a reduction in elongation efficiency and termination of transcription by RNA polymerase II in animal systems (Connelly and Manley, 1989) .
  • This internal gene fragment or inhibitory zone may itself comprise a plurality of inhibitory zones which reduce Bt ICP expression levels or which interact directly or indirectly with other zones to inhibit or interfere with expression. Codon usage of this inhibitory zone has been modified in a second step by substituting A - T with G - C without affecting the amino acid sequence.
  • this internal 326 bp fragment (fig. 6b) has been replaced with a modified Bt ICP fragment of this invention containing 59 modified codons.
  • the effect of such modification of this inhibitory zone on Bt ICP expression has been analyzed both in transient and stable plant transformants. The results show that such modification of codon usage causes a significant increase of Bt ICP expression levels and hence improved insect-resistance.
  • N-terminal deletion mutants of the bt2 gene have been made by deleting the first N- terminal 28 amino acids (H ⁇ fte et al., 1986). It is known for the bt2 gene that the first 28 codons can be deleted without loss of toxicity (H ⁇ fte et al., 1986; Vaeck et al., 1987). Also, codon usage for three codons, 29 to 31, has been changed in accordance with this invention by replacing A - T with G - C without affecting the amino acid sequence. Furthermore, an optimal translation initiation (ATG) site was created based on the consensus sequence of Joshi (1987) as shown in fig. 6a. Plants transformed with this modified Bt ICP gene show significantly higher Bt ICP expression levels.
  • a modified Bt ICP gene of the invention can be stably inserted in a conventional manner into the nuclear genome of a plant cell, and the so-transformed plant cell can be used to produce a transgenic plant showing improved expression of the Bt ICP gene.
  • a disarmed Ti-plasmid, containing the modified Bt ICP gene, in Agrobacterium can be used to transform a plant cell using the procedures described, for example, in EP 116,718 and EP 270,822, PCT publication 84/02913, EPA 87400544.0 and Gould et al. (1991) (which are incorporated herein by reference) .
  • Preferred Ti-plasmid vectors contain the foreign DNA sequence between the border sequence, or at least located to the left of the right border sequence, of the T-DNA of the Ti-plasmid.
  • other types of vectors can be used to transform the plant cell, using procedures such as direct gene transfer (as described, for example, in EP 233,247), pollen mediated transformation (as described, for example, in EP 270,356, PCT publication WO 85/01856, and US patent 4,684,611), plant RNA virus-mediated transformation (as described, for example, in EP 67,553 and US patent 4,407,956), liposome-mediated transformation (as described, for example, in US patent 4,536,475) and other methods such as the recently described methods for transforming certain lines of corn (Fromm et al., 1990; Gordon-Kamm et al., 1990).
  • the modified Bt ICP gene is inserted in a plant genome downstream of, and under the control of, a promoter which can direct the expression of the gene in the plant cells.
  • promoters include, but are not limited to, the strong constitutive 35S promoter (Odell et al., 1985) of cauliflower mosaic virus; 35S promoters have been obtained from different isolates (Hull and Howell, Virology 86, 482-493 (1987)).
  • Other preferred promoters include the TR1* promoter and the TR2' promoter (Velten et al., 1984).
  • a promoter can be utilized which is not constitutive but rather is specific for one or more tissues or organs.
  • the modified Bt ICP gene can be selectively expressed in the green tissues of a plant by placing the gene under the control of a light-inducible promoter such as the promoter of the ribulose - 1,5 - phosphate - carboxylase small subunit gene as described in EPA 86300291.1.
  • a light-inducible promoter such as the promoter of the ribulose - 1,5 - phosphate - carboxylase small subunit gene as described in EPA 86300291.1.
  • Another alternative is to use a promoter whose expression is inducible by temperature or chemical factors.
  • the modified Bt ICP gene be inserted upstream of suitable 3• transcription regulation signals (i.e., transcript 3 1 end formation and polyadenylation signals) such as the 3' untranslated end of the octopine synthase gene (Gielen et al., 1984) or T-DNA gene .7 (Velten and Schell, 1985).
  • suitable 3• transcription regulation signals i.e., transcript 3 1 end formation and polyadenylation signals
  • transcript 3 1 end formation and polyadenylation signals such as the 3' untranslated end of the octopine synthase gene (Gielen et al., 1984) or T-DNA gene .7 (Velten and Schell, 1985).
  • the resulting transformed plant of this invention shows improved expression of the modified Bt ICP gene and hence is characterized by the production of high levels of Bt ICP.
  • Such a plant can be used in a conventional breeding scheme to produce more transformed plants with the same improved insect- resistance characteristics or to introduce the modified B
  • Seeds which are obtained from the transformed plants, contain the modified BtlCP gene as a stable genomic insert. Furthermore, at least two modified BtlCP genes, coding for two non-competitively binding anti- Lepidopteran or anti-Coleopteran Bt ICPs, can be cloned into a plant expression vector (EPA 89401499.2). Plants transformed with such a vector are characterized by the simultaneous expression of at least two modified BtlCP genes. The resulting transgenic plant is particularly useful to prevent or delay development of resistance to Bt ICP of insects feeding on the plant.
  • Fig.l Comparison of the transcription initiation frequency of RNA polymerase II complexes in nuclei of N28-220. Hybridisation efficiencies of labeled nptll mRNA and Bt ICP mRNA with their complementary DNA counterparts present on a Southern blot were compared. DNA fragments were obtained from a digest of plasmid pGSH163. A schematic view of the region is given. The lengths of the fragments blotted on Hybond-N filter (1) , the homologous genes on plasmid pGSH163 (2) , and the densitometric values (3) are as follows:
  • Fig. 2a Determination of the distribution of the RNA polymerase II complexes on the Bt ICP coding sequence in nuclei of N28-220.
  • the restriction fragments and scanning values are given in the table and figure.
  • the scanning value is proportional to "X", the size of the DNA fragment and the # UTP per RNA fragment hybridising.
  • "X” is directly proportional to the number of RNA polymerases passing through the DNA fragment.
  • "X” is proportional to the scanning value divided by the number of UTPs.
  • the X values of the different restriction fragments are shown in the figure.
  • Fig. 2b Schematic view of nine bt884 DNA fragments that were inserted into the polylinker of M13 vectors, MP18 and MP19 (Yanisch-Perron et al., 1985).
  • the Bt ICP coding sequence is shown from AUG to 1600 nucleotides downstream. The relevant restriction sites and sizes of the DNA fragments are indicated. The nucleotide numbering is relative to the AUG.
  • the subclones were named pJD71, pJD72, pJD73, etc. (to pJD79) , as indicated.
  • the inserts were oriented into the M13 vector such that single standed M13 carried the fragments of the Bt ICP coding sequence in an anti- sense orientation.
  • Fig. 2c Schematic representation of three nuclear run-on analyses with N28-220 nuclei as described by Cox and Goldberg (1988) . Assays were performed for periods of 5, 10 and 30 minutes. The labeled nuclear RNA was allowed to hybridize with 5 ⁇ g of single stranded pJD71-pJD79 and MP18 DNA, which were immobilised on nylon membranes. The membranes were autoradiographed, and densitometric values were obtained by scanning the autoradiographs. The abscissa shows the nucleotide position relative to the AUG of the Bt (i.e., bt2) coding sequence. The center of each of the single stranded Bt DNA fragments is indicated in the graph.
  • Bt i.e., bt2
  • the ordinate gives the relative hybridisation signal for each fragment corrected for the number of dATPs in the fragment and adjusted to 100% for the value of pJD71 for each of the three incubation periods. All values are corrected for non-specific hybridisation to single stranded MP18 DNA. The relative values are a measure for the reactivation of bt mRNA synthesis by RNA polymerase II. The assay does not distinguish between the number of mRNA extensions and the length of mRNA extensions.
  • Fig. 3 Construction of deletion mutants of the bt860-neo gene to measure the effect on cytoplasmic Bt ICP mRNA levels.
  • the parental vector pVE36 is shown. The following deletion mutants were generated:
  • PJD50 was derived from pVE36 by digesting with BamHI and Sphl. The 5'and 3' protruding ends were filled in with Klenow
  • the treated DNA was ligated and then used to transform
  • PJD51 was derived from pVE36 by digesting with Spel and Sphl. The 5•and 3' protruding ends were filled in with Klenow
  • PJD52 was derived from pVE36 by digesting with EcoRV and Sphl. The 5' nd 3 « protruding ends were filled in with Klenow DNA polymerase I enzyme. The treated DNA was ligated and then used to transform MC1061 cells. Transformants were selected for amp r phenotype.
  • PJD53 was derived from pVE36 by digesting with Xcal and Sphl. The 3* protruding ends were filled in with Klenow DNA polymerase I enzyme. The treated DNA was ligated and then used to transform MC1061 cells. Transformants were selected for amp r phenotype.
  • PJD54 was derived from pVE36 by digesting with Aflll and Sphl. The 5' and 3 « protruding ends were filled in with Klenow DNA polymerase I enzyme. The treated DNA was ligated and then used to transform MC1061 cells. Transformants were selected for amp 1" phenotype.
  • PJD55 was derived from pVE36 by digesting with Clal and Sphl. The 5 « and 3 1 protruding ends were filled in with Klenow DNA polymerase I enzyme. The treated DNA was ligated and then used to transform MC1061 cells. Transformants were selected for amp 1" phenotype.
  • PJD56 pJD56 was derived from pVE36 by digesting with Xhol and Sphl. The 5' and 3 « protruding ends were filled in with Klenow DNA polymerase I enzyme. The treated DNA was ligated and then used to transform MC1061 cells. Transformants were selected for amp r phenotype.
  • PJD57 pJD57 was derived from pVE36 by digesting with Aflll and BamHI. The 5 « and 3' protruding ends were filled in with Klenow DNA polymerase I enzyme. The treated DNA was ligated and then used to transform MC1061 cells. Transformants were selected for amp r phenotype.
  • PJD58 was derived from pVE36 by digesting with Xcal and BamHI. The 5' protruding ends were filled in with Klenow DNA polymerase I enzyme. The treated DNA was ligated and then used to transform MC1061 cells. Transformants were selected for amp r phenotype.
  • pJD59 was derived from pVE36 by digesting with EcoRV and BamHI. The 5' protruding ends were filled in with Klenow DNA polymerase I enzyme. The treated DNA was ligated and then used to transform MC1061 cells. Transformants were selected for amp r phenotype.
  • PJD60 was derived from pVE36 by digesting with Spel and BamHI. The 5* protruding ends were filled in with Klenow DNA polymerase I enzyme. The treated DNA was ligated and then used to transform MC1061 cells. Transformants were selected for amp r phenotype.
  • PJD61 was derived from PJD50.
  • PVE36 was digested with Xbal and filled in with Klenow polymerase I.
  • PJD50 was linearized with BamHI and filled in with Klenow polymerase I.
  • the 375bp Xbal fragment of PVE36 was ligated in the filled in BamHI of pJD50.
  • the ligation mixture was used to transform MC1061 cells. Transformants were selected for amp r phenotype.
  • PJD62 was derived from PJD50.
  • PVE36 was digested with Xcal and EcoRV.
  • PJD50 was linearized with BamHI and filled in with Klenow polymerase I.
  • the 367bp Xcal-EcoRV fragment of PVE36 was ligated in the filled in BamHI of pJD50.
  • the ligation mixture was used to transform MC1061 cells. Transformants were selected for amp r phenotype.
  • PJD63 was derived from PJD50.
  • PVE36 was digested with Xcal and EcoRV.
  • PJD50 was linearized with BamHI and filled in with Klenow polymerase I.
  • the 474bp Xcal-EcoRV fragment of PVE36 was ligated in the filled in BamHI of pJD50.
  • the ligation mixture was used to transform MC1061 cells. Transformants were selected for amp r phenotype.
  • PJD64 was derived from PJD50.
  • PVE36 was digested with EcoRI and EcoRV and filled in with Klenow polymerase I.
  • PJD50 was linearized with BamHI and filled in with Klenow polymerase I.
  • the 458bp EcoRI-EcoRV fragment of PVE36 was ligated in the filled in BamHI of pJD50.
  • the ligation mixture was used to transform MC1061 cells. Transformants were selected for amp r phenotype.
  • PJD65 was derived from PJD50.
  • PVE36 was digested with EcoRI and Xbal and filled in with Klenow polymerase I.
  • PJD50 was linearized with BamHI and filled in with Klenow polymerase I.
  • the 327bp EcoRI-Xbal fragment of PVE36 was ligated in the filled in BamHI of pJD50.
  • the ligation mixture was used to transform MC1061 cells. Transformants were selected for amp r phenotype.
  • PJD66 was derived from PJD50.
  • PVE36 was digested with Spel and Xcal and filled in with Klenow polymerase I.
  • PJD50 was linearized with BamHI and filled in with Klenow polymerase I.
  • the 1021bp Spel-Xcal fragment of PVE36 was ligated in the filled in BamHI of pJD50.
  • the ligation mixture was used to transform MC1061 cells. Transformants were selected for amp r phenotype.
  • PPS56D1 was derived from PJD56 by digesting with EcoRV. The treated DNA was ligated and then used to transform MC1061 cells. Transformants were selected for amp r phenotype.
  • PPS56D2 was derived from PJD56 by digesting with Xcal and Aflll. The 5' protruding ends were filled in with Klenow polymerase I. The treated DNA was ligated and then used to transform MC1061 cells. Transformants were selected for amp r phenotype.
  • PPS56D3 PPS56D3 was derived from PJD56 by digesting with Spel and EcoRV. The 5' protruding ends were filled in with Klenow polymerase I. The treated DNA was ligated and then used to transform MC1061 cells. Transformants were selected for amp r phenotype.
  • PPS56D4 PPS56D4 was derived from PJD56 by digesting with Xcal and partially with
  • the treated DNA was ligated and then used to transform MC1061 cells. Transformants were selected for amp r phenotype.
  • PPS56D6 PPS56D6 was derived from PJD56 by digesting with Spel and partially with EcoRV. The 5' protruding ends were filled in with Klenow polymerase I. The treated DNA was ligated and then used to transform MC1061 cells. Transformants were selected for amp r phenotype.
  • PPS56D7 was derived from PJD56 by digesting with Spel and Xcal. The 5* protruding ends were filled in with Klenow polymerase I. The treated DNA was ligated and then used to transform MC1061 cells. Transformants were selected for amp r phenotype.
  • PPS56D8 PPS56D8 was derived from PPS56D2 by digesting with Spel and partially with EcoRV. The 5' protruding ends were filled in with Klenow polymerase I. The treated DNA was ligated and then used to transform MC1061 cells. Transformants were selected for amp 1* phenotype.
  • Fig. 4 Effect of deletions in the Bt ICP coding sequence on cytoplasmic Bt ICP mRNA levels.
  • the cytoplasmic mRNA levels specified by the invariable cat reference gene and the different Bt ICP deletion mutants described in fig. 3 are listed in the table. The measurements were converted into relative Bt ICP mRNA abundances.
  • Bt ICP and cat mRNA quantizations were done as described by Cornelissen (1989) . Total RNA was slot blotted and hybridised with radioactively labeled RNA complementary to the neo and cat coding sequences. Values were quantitated with the aid of calibration curves of cold cat and Bt ICP riboprobe transcripts.
  • Fig. 5 Relative transcript levels produced by the deletion derivatives of pVE36.
  • Fig. 6a Schematic presentation of the synthetic DNA sequences used to introduce a N-terminal deletion and a change of the codons 29, 30 and 31 of the bt2 coding sequence.
  • the oligo nucleotides were annealed according to Engler et al. (1988) and cloned into the BstXI restriction site of plasmid pVE36, yielding pPS027.
  • the 7360 bp fragment of pPS027 was ligated to the the 1177 bp Clal restriction fragment of pVE36, yielding plasmid pPS028.
  • pPS028 is identical to pVE36 apart for the N- terminal modification.
  • Fig. 6b Schematic presentation of the synthetic DNA sequences used to introduce an internal modification into the bt2 coding sequence.
  • the oligonucleotides were annealed and ligated as described by Engler et al. (1988) and the resulting concatemeric DNA fragment was cut with the restriction enzymes Xbal and EcoRI to release the modified 327 bp Xbal-EcoRI restriction fragment.
  • Plasmid pPS024 was linearised by digestion with restriction enzyme Xbal and the 375 bp Xbal restriction fragment of pPS023 was introduced resulting in pPS025.
  • pPS029 is identical to pVE36 but carries both the amino- terminal modification and the internal modification of the Bt ICP coding sequence.
  • Fig. 6c Nucleotide sequences 800 to 4000 of the plasmids pVE36 and pPS029. "x" refers to not known nucleotides.
  • Fig. 7 Schematic presentation of the effect of the mutations on the AT content of the Bt ICP plant gene. The modified regions are indicated.
  • Fig. 8a Schematic presentation of the plasmid constructions used in the transient expression assay. The relevant genes are indicated.
  • Fig. 8b Accumulation profiles of CAT (Neumann et al., 1987) and the modified BtlCP (Engvall and Pesce, 1978) in a typical transient expression assay.
  • RNA polymerase II complexes to initiate transcription at chimaeric BtlCP plant genes was studied, using transgenic plant N28-220 which is described by Vaeck et al. (1987) and contains copies of the T-DNA of plasmid pGSH163 This T-DNA carries the chimaeric plant genes P TR2 bt8843'g7 and P ⁇ .neoS'ocs. Nuclei of 25 g of induced leaves of N28-220 were prepared according to Cox and Goldberg (1988) and stored the nuclei at a temperature of -70°C.
  • This method causes the nascent precursor mRNA chains and the RNA polymerase II complexes to halt while the complexes remain associated at the DNA.
  • a batch of these nuclei was assayed for the ability to incorporate radioactively labeled UTP as a measure for the transcriptional viability of the nuclei (Cox and Goldberg (1988) .
  • This incorporation could be successfully repressed by addition of ⁇ -amanitin to a final concentration of 2 ⁇ g/ml. This shows that the UTP incorporation was due to transcript elongation by RNA polymerase II and that RNA synthesis on the protein coding genes which are occupied by RNA polymerase II can be reactivated under the appropriate experimental conditions.
  • the radioactive RNA synthesized is a direct representation of the distribution of the RNA polymerases II complexes on the DNA in the nuclei.
  • the DNA of N28-220 carries two genes which can be assayed, namely the chimaeric neo gene and the chimaeric Bt ICP gene, it is possible to compare the distribution of RNA polymerase II complexes on these two genes.
  • the radioactive RNA was extracted from the nuclei according to Cox and Goldberg (1988) and used as a probe in a conventional Southern hybridisation.
  • the Southern blot contained DNA fragments carrying the Bt ICP and neo coding sequences in a molar excess relative to the neo and Bt ICP RNA species present in the radioactive probe.
  • a detailed description of the Southern blot is given in fig. l.
  • the hybridisation experiment resulted in hybridisation signals to both the neo and Bt ICP coding sequences
  • the nuclei were incubated as described by Cox and Goldberg (1988) to synthesize radioactively labeled RNA.
  • the radioactive RNA was extracted as described previously to provide a probe for a Southern hybridisation.
  • the Southern blot prepared for this experiment contained several fragments of the Bt ICP coding sequence in molar excess relative to the complementary RNA present in the probe.
  • the rationale of the experiment was that if the RNA polymerase II complexes were equally distributed over the Bt ICP coding region, the hybridisation with the different Bt ICP DNA fragments present on the Southern blot would be proportional to the size and dATP content of the different fragments.
  • a detailed description of the DNA fragments present on the Southern is given in fig 2a.
  • the hybridisation of the radioactive RNA extracted from the nuclei of N28-220 with the Southern revealed that the complete Bt ICP coding sequence as present in N28-220 is transcribed by RNA polymerase II.
  • the site(s) involved in reducing the RNA polymerase II elongation were then determined more accurately.
  • Nine M13 derivatives were made that carry overlapping fragments of the Bt2 coding sequence spanning the region from the AUG to 1584 nucleotides downstream.
  • the inserts were oriented into the vector such that, in single stranded M13 derivatives, the Bt sequences were complementary to the Bt transcript.
  • a schematic view of the M13 clones is given in fig. 2b.
  • the results are shown in fig. 2c.
  • the data for the 5 minute incubation show that, n vivo, at a very discrete inhibitory zone along the bt2 coding sequence, one or more factors interfere with transcript elongation and that such factor(s) remain present in such inhibitory zone during the course of the in vitro mRNA extension reaction.
  • Increased incubation periods show that, on a subset of DNA templates, RNA synthesis resumed downstream of such inhibitory zone in this assay without significantly removing the inhibition in the inhibitory zone itself.
  • the data indicate that:
  • the inhibitory zone causes the RNA polymerases to pause and not to terminate.
  • RNA polymerase elongation downstream of the inhibitory zone, is done by a large number of polymerases on the relatively small fraction of the Bt DNA templates.
  • low cytoplasmic Bt mRNA levels are due at least in part to inefficient production of precursor mRNA caused by inefficient elongation of a nascent transcript and/or stalling of RNA polymerase II complexes from transcribing at an inhibitory zone.
  • the inhibitory zone was assayed for its ability to interact with proteins present in nuclei of tobacco protoplasts.
  • a crude nuclear extract was prepared from tobacco SRI leaf protoplasts according to Luthe and Quatrano (1980) and used for filter binding assay essentially as described by Diffley and Still an (1986) .
  • 100 ng samples of protein extract were mixed with different amounts of radioactively labeled 532 bp Xbal-Accl bt884 DNA fragment, ranging from 0 to 1670 picomolar, in a final volume of 0.150 ml binding buffer (10 mM Tris pH 7.5, 50 mM NaCl, 1 mM DTT, 1 mM EDTA and 5% glycerol) .
  • the previous two examples demonstrate that the Bt ICP coding sequence in a chimaeric plant gene negatively affects the cytoplasmic Bt ICP mRNA level directed by the chimaeric plant gene. It is shown that this negative control is not at the level of transcription initiation but at least in part due to a reduced ability of RNA polymerase II to generate precursor Bt ICP mRNA.
  • a deletion analysis of the chimaeric Bt ICP plant gene was performed to identify whether impaired transcription elongation is the exclusive mechanism by which the Bt ICP sequence interferes with gene expression. The rationale of the experiment is that the introduction of specific deletions in the Bt ICP coding region could remove or inactivate the sequence element(s) responsible for the negative control.
  • the relative mRNA abundances were calculated using a correction factor provided by the mRNA level specified by the cat reference gene present on the same plasmid as the mutant Bt ICP gene.
  • Four hours after introduction of the genes the tobacco leaf protoplasts were harvested, and total RNA was prepared and analysed (fig. 4).
  • the mutants nos. 50-60 (fig. 3) show that progressive deletions of the carboxy-terminal part or the amino-terminal part of the Bt ICP coding sequence result in a gradually increasing neo transcript level. As there are not very abrupt changes in transcript levels, these results suggest that the low transcript level produced by full length Bt ICP genes is controlled by a number of signals.
  • Fig. 5 suggests that hybrid Bt ICP-neo transcript levels drop with increasing length of the Bt ICP sequence.
  • the mutants nos. 61-66 (fig. 3) form an exception as they show in average a low transcript level relative to the length of the Bt ICP sequence.
  • Cytoplasmic bt2 mRNA steady state levels in transgenic leaf protoplasts of N28-220 are normally found to be below 1 transcript per cell.
  • the steady state level is determined by, and is proportional to, the number of bt2 transcripts entering per time unit the cytoplasm and the cytoplasmic half-life of the transcript.
  • steady state levels are achieved, the absolute numbers of transcripts entering and leaving the cytoplasmic bt2 mRNA pool are equal.
  • the cytoplasmic half- life and cytoplasmic steady state level of the bt2 transcript will reveal whether its cytoplasmic steady state level is due to a relatively low import of bt2 transcript, a relatively high turnover (i.e., conversion to a protein) rate, or a combination of both.
  • cytoplasmic turnover of bt884 transcripts was determined according to Gallie et al. (1989) .
  • a capped and polyadenylated synthetic bt884 mRNA was produced in vitro according to protocols of Promega Corporation (Madison, Wisconsin, USA) and introduced into tobacco leaf protoplasts simultaneously with a synthetic bar
  • the low cytoplasmic steady state level of the bt884 transcripts is, therefore, caused by a lack of import of transcripts into the cytoplasm.
  • the expression defect of the bt884 gene has to be restored by introduction of modifications in the bt884 coding sequence that improve the expression pathway in the nucleus.
  • bt!4, bt!5 and bt!8 genes like the bt884 gene, must be deficient in exporting high levels of bt transcript to the cytoplasm, and to improve the expression of such genes, it is necessary to modify their coding sequences so that nuclear events, which interfere with efficient gene expression, are avoided or ameliorated.
  • the synthetic bar transcripts had a length of 783 bases and included a cap, the TMV leader (77 bases, Danthinne and Van Emmelo, 1990) , the bar coding sequence (552 bases; De Block et al., 1987), a trailer of 52 nucleotides consisting of the bases GAUCA CGCGA AUU and 39 bases from the pGEM-3Z (Promega) polylinker (Kpnl (T4 DNA pol.)-HindIII (T4 DNA pol.), and a poly(A) of the composition (A) 33 G(A) 32 G(A) 32 , followed by the nucleotides GCU.
  • the synthetic bt884 transcripts had a length of 2066 bases and included a cap, the TMV leader (77 bases) , the bt884 coding sequence followed by the trailer until the Klenow treated Pstl site (1843 nucleotides) , the trailer continued with AAUUC CGGGG AUCAA UU, 39 bases of the pGEM-3Z polylinker and the (A) 3 G(A) 32 G(A) 21 poly(A) , followed by the nucleotides CG.
  • the synthetic bt!4 transcripts had a length of 2289 bases and included a cap, the TMV leader (77 bases) , the bt!4 coding sequence till the Klenow treated Bell site (2023 bases) , plus 26 supplementary nucleotides CG UCG ACC UGC AGC CAA GCU UGC UGA, a trailer starting with UUGAU UGACC GGAUC CGGCU CUAGA AUU, followed by 39 bases of the pGEM-3Z polylinker, and the (A) 33 G(A) 32 G(A) 21 poly(A), followed by the nucleotides CGGUA CCC.
  • the synthetic bt!5 transcripts had a length of 2198 bases and included a cap, the TMV leader (77 bases) the btl5 coding sequence as in pVE35 (PCT publication WO90/15139) followed by the trailer till the Klenow treated BamHI site (1989 bases), the trailer then continued with AAUU, 39 bases of the pGEM-3Z polylinker and the (A) ⁇ G(A) 32 G(A) 21 poly(A) , followed by the nucleotides CG.
  • the synthetic bt!8 transcripts had a length of 2184 bases and included a cap, the TMV leader (77 bases) the btl ⁇ coding sequence until the Klenow treated BcLI site (1918 bases), followed by 26 nucleotides until the translation stop CG UCG ACC UGC AGC CAA GCU UGC UGA, a trailer starting with UUGAU UGACC GGAUC GAUCC GGCUC AGAUC AAUU, 39 bases of the pGEM-3Z polylinker and the (A) 33 G(A) 32 G(A) 21 poly(A), followed by the nucleotides CG.
  • Examples 1-4 show that the expression in a plant of a Bt ICP gene is negatively affected by the Bt ICP coding sequence at both transcriptional and post- transcriptional levels, but principally by nuclear events. These examples also show that the control of expression is not confined to a specific DNA sequence within the Bt ICP coding sequence. Instead, the negative effect on gene expression is an intrinsic property of the Bt ICP coding sequence. On this basis, it is believed that, by directed change of the DNA sequence of the Bt ICP coding region, an improvement of gene expression will occur. The improvement will be of a cumulative type as the negative influence of the Bt ICP coding region is spread over the complete coding sequence. Similarly, an improvement of gene expression will be obtained by reduction of the length of the Bt ICP coding sequence. This improvement will have a cumulative effect if used in combination with modifications of the Bt ICP coding region.
  • the expression properties of the modified BtlCP gene and the parental bt860-neo gene were compared in a transient expression system as described by Cornelissen and Vandewiele (1989) and Denecke et al. (1989).
  • the accumulation profiles of the genes under study were compared by relating their profiles to the profile of a reference gene present in the same experiment.
  • Fig. 8a shows the vectors used in the assay
  • fig. 8b shows that the accumulation of the reference CAT protein is nearly identical in both experiments. It is not possible to measure the accumulation of Bt ICP encoded by the parental bt860-neo gene, but the modified Bt ICP gene clearly directs an increased synthesis of Bt ICP.
  • Example 6 Cloning and Expression of Modified BT ICP Genes in Tobacco and Potato Plants Using the procedures described in US patent application 821,582, filed January 22, 1986, and EPA 86300291.1, EPA 88402115.5 and EPA 89400428.2, the modified Bt ICP (i.e., bt2) genes of figs. 6 and 7 are inserted into the intermediate T-DNA vector, pGSH1160 (Deblaere et al., 1988) between the vector's T-DNA terminal border repeat sequences.
  • bt2 modified Bt ICP
  • the modified Bt ICP genes are placed under the control of the strong TR2' promoter (Velten et al., 1984) and are fused to the transcript 3' end formation and polyadenylation signals of the T-DNA gene 7 (Velten and Schell, 1985).
  • the translation initiation context or site are changed in accordance with the Joshi consensus sequence (Joshi, 1987) in order to optimize the translation initiation in plant cells.
  • an oligo duplex (figs. 6a and 6b) is introduced to create the following sequence at translation initiation site: AAAACCATGGCT.
  • an additional codon i.e., GCT
  • Kpnl and BstXI sites are created upstream of the ATG translation initiation codon.
  • the intermediate plant expression vectors containing the modified BtlCP gene, are transferred into the Agrobacterium strain C58C1 Rif R (US patent application 821,582; EPA 86300291.1) carrying the disarmed Ti- plasmid pGV2260 (Vaeck et al., 1987). Selection for spectinomycin resistance yields cointegrated plasmids, consisting of pGV2260 and the respective intermediate plant expression vectors.
  • Each of these recombinant Agrobacterium strains is then used to transform different tobacco plant cells (Nicotiania tabacum) and potato plant cells (Solanum tuberosum) so that the modified Bt ICP genes are contained in, and expressed by, different tobacco and potato plant cells.
  • the transgenic tobacco plants containing the modified Bt ICP genes are analyzed with an ELISA assay. These plants are characterized by a significant increase in levels of Bt (Bt2) proteins, compared to a transgenic tobacco plant containing a non-modified Bt ICP (bt2) gene.
  • the insecticidal activity of the expression products of the modified Bt ICP (bt2) genes in leaves of transformed tobacco and potato plants is evaluated by recording the growth rate and mortality of larvae of Tobacco hornworm (Manduca sexta) , Tobacco budworm (Heliotis virescens) and potato tubermoth (Phthorimaea operculella) fed on leaves of these two types of plants. These results are compared with the growth rate of larvae fed leaves from tobacco and potato plants transformed with the unmodified or parental Bt ICP (bt2) gene and from untransformed potato and tobacco plants. Toxicity assays are performed as described in EPA 88402115.5 and EPA 86300291.1.
  • a significantly higher mortality rate is obtained among larvae fed on leaves of transformed plants containing and expressing the modified Bt ICP genes.
  • Tobacco and potato plants containing the modified Bt ICP genes show considerably higher expression levels of Bt ICPs compared to tobacco and potato plants containing the unmodified Bt ICP gene.
  • this invention is not limited to tobacco and potato plants transformed with the modified Bt ICP gene. It includes any plant, such as tomato, alfalfa, sunflowers, corn, cotton, soybean, sugar beets, rapeseed, brassicas and other vegetables, transformed with the modified Bt ICP gene.
  • the invention limited to the use of Agrobacterium tumefaciens Ti-plasmids for transforming plant cells with a modified Bt ICP gene.
  • Other known techniques for plant transformation such as by means of liposomes, by electroporation or by vector systems based on plant viruses or pollen, can be used for transforming monocotyledonons and dicotyledons with such a modified Bt ICP gene.

Landscapes

  • Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Biomedical Technology (AREA)
  • Biophysics (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Zoology (AREA)
  • Pest Control & Pesticides (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Physics & Mathematics (AREA)
  • Cell Biology (AREA)
  • Plant Pathology (AREA)
  • Insects & Arthropods (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Microbiology (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Breeding Of Plants And Reproduction By Means Of Culturing (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
  • Peptides Or Proteins (AREA)

Abstract

Un fragment d'ADN qui code la totalité ou une partie insecticide d'une protéine cristalline de Bacillus thuringiensis, est modifié par le changement des séquences A et T en séquences correspondantes G et C qui codent les mêmes acides aminés.
EP91907836A 1990-04-18 1991-04-17 GENES MODIFIES DU $i(BACILLUS THURINGIENSIS) CODANT UNE PROTEINE CRISTALLINE INSECTICIDE ET LEUR EXPRESSION DANS DES CELLULES DE PLANTES Ceased EP0528819A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP90401055 1990-04-18
EP90401055 1990-04-18

Publications (1)

Publication Number Publication Date
EP0528819A1 true EP0528819A1 (fr) 1993-03-03

Family

ID=8205702

Family Applications (1)

Application Number Title Priority Date Filing Date
EP91907836A Ceased EP0528819A1 (fr) 1990-04-18 1991-04-17 GENES MODIFIES DU $i(BACILLUS THURINGIENSIS) CODANT UNE PROTEINE CRISTALLINE INSECTICIDE ET LEUR EXPRESSION DANS DES CELLULES DE PLANTES

Country Status (5)

Country Link
EP (1) EP0528819A1 (fr)
JP (1) JPH05506578A (fr)
AU (1) AU651101B2 (fr)
CA (1) CA2080584C (fr)
WO (1) WO1991016432A1 (fr)

Families Citing this family (94)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6403865B1 (en) 1990-08-24 2002-06-11 Syngenta Investment Corp. Method of producing transgenic maize using direct transformation of commercially important genotypes
UA48104C2 (uk) * 1991-10-04 2002-08-15 Новартіс Аг Фрагмент днк, який містить послідовність,що кодує інсектицидний протеїн, оптимізовану для кукурудзи,фрагмент днк, який забезпечує направлену бажану для серцевини стебла експресію зв'язаного з нею структурного гена в рослині, фрагмент днк, який забезпечує специфічну для пилку експресію зв`язаного з нею структурного гена в рослині, рекомбінантна молекула днк, спосіб одержання оптимізованої для кукурудзи кодуючої послідовності інсектицидного протеїну, спосіб захисту рослин кукурудзи щонайменше від однієї комахи-шкідника
AU657584B2 (en) * 1991-10-30 1995-03-16 Plant Genetic Systems N.V. Modified genes and their expression in plant cells
TW261517B (fr) * 1991-11-29 1995-11-01 Mitsubishi Shozi Kk
US5849870A (en) * 1993-03-25 1998-12-15 Novartis Finance Corporation Pesticidal proteins and strains
US5877012A (en) * 1993-03-25 1999-03-02 Novartis Finance Corporation Class of proteins for the control of plant pests
WO1994021795A1 (fr) * 1993-03-25 1994-09-29 Ciba-Geigy Ag Nouvelles souches et proteines pesticides
WO1994024264A1 (fr) 1993-04-09 1994-10-27 Plant Genetic Systems N.V. Nouvelles souches de bacille thuringiensis et leurs proteines insecticides
ATE443437T1 (de) * 1995-10-13 2009-10-15 Dow Agrosciences Llc Modifiziertes bacillus thuringiensis gen zur kontrolle von lepidoptera in pflanzen
US5994526A (en) * 1996-06-21 1999-11-30 Plant Genetic Systems Gene expression in plants
TR199902426T2 (xx) 1997-04-03 2000-06-21 Novartis Ag. Bitki b�ceklerinin kontrol�.
CA2288895A1 (fr) 1997-08-12 1999-02-18 North Carolina State University Lentille d'eau genetiquement mise au point
US5929301A (en) * 1997-11-18 1999-07-27 Pioneer Hi-Bred International Nucleic acid sequence encoding FLP recombinase
US6720475B1 (en) 1997-11-18 2004-04-13 Pioneer Hi-Bred International, Inc. Modified nucleic acid sequence encoding FLP recombinase
US6121521A (en) * 1998-04-01 2000-09-19 Novartis Ag Chimeric insecticidal protein and DNA coding therefor
WO2001047952A2 (fr) 1999-12-28 2001-07-05 Bayer Cropscience N.V. Proteines insecticides provenant de bacillus thuringiensis
US7879540B1 (en) 2000-08-24 2011-02-01 Promega Corporation Synthetic nucleic acid molecule compositions and methods of preparation
AU8847801A (en) 2000-08-25 2002-03-04 Basf Plant Science Gmbh Plant polynucleotides encoding novel prenyl proteases
ES2397549T3 (es) 2001-01-09 2013-03-07 Bayer Cropscience Nv Proteínas insecticidas de Bacillus thuringiensis
CA2459961A1 (fr) 2001-09-05 2003-03-13 Basf Plant Science Gmbh Polypeptides associes au stress regule par la proteine phosphatase et leurs procedes d'utilisation dans des plantes
US7220585B2 (en) 2001-11-09 2007-05-22 Basf Plant Science Gmbh Transcription factor stress-related polypeptides and methods of use in plants
CN100497378C (zh) 2002-03-22 2009-06-10 拜尔生物科学公司 新的苏云金芽孢杆菌杀昆虫蛋白质
AU2002319236A1 (en) 2002-06-14 2003-12-31 Monier Tadros Method for the production of protamine
EP1551218B1 (fr) 2002-07-10 2017-05-17 The Department of Agriculture, Western Australia Plants de ble presentant une resistance accrue a un herbicide a base d'imidazolinone
PT1589807E (pt) 2002-12-06 2012-02-02 Del Monte Fresh Produce Company Plantas transgénicas de ananás com níveis modificados de carotenóides e métodos da sua produção
AU2004230490C1 (en) 2003-04-15 2012-08-16 Basf Plant Science Gmbh Nucleic acid sequences encoding proteins associated with abiotic stress response and plant cells and plants with increased tolerance to environmental stress
EP1633875B1 (fr) 2003-05-28 2012-05-02 Basf Se Plantes de ble presentant une tolerance accrue aux herbicides d'imidazolinone
UY28495A1 (es) 2003-08-29 2005-03-31 Inst Nac De Tecnologia Agropec Plantas de arroz que tienen una mayor tolerancia a los herbicidas de imidazolinona
US7728118B2 (en) 2004-09-17 2010-06-01 Promega Corporation Synthetic nucleic acid molecule compositions and methods of preparation
AU2005286428B2 (en) 2004-09-24 2012-08-23 Basf Plant Science Gmbh Nucleic acid sequences encoding proteins associated with abiotic stress response and plant cells and plants with increased tolerance to environmental stress
EP2166098B1 (fr) 2004-10-05 2013-11-06 SunGene GmbH Cassettes d'expression constitutive pour la régulation de l'expression chez les plantes
EP1655364A3 (fr) 2004-11-05 2006-08-02 BASF Plant Science GmbH Cassettes d'expression pour une expression préférentielle dans les graines.
EP1662000B1 (fr) 2004-11-25 2011-03-30 SunGene GmbH Cassettes d'expression pour l'expression préférée dans des cellules stomatiques de plantes
EP1666599A3 (fr) 2004-12-04 2006-07-12 SunGene GmbH Cassettes d'expression pour l'expression préférée dans les cellules du mésophylle et/ou de l'épiderme de plantes
EP1669455B1 (fr) 2004-12-08 2009-10-28 SunGene GmbH Cassettes d'expression pour l'expression spécifique aux tissus vasculaires des plantes
EP1669456A3 (fr) 2004-12-11 2006-07-12 SunGene GmbH Cassettes d'expression pour l'expression preférentielle dans les méristèmes de plantes
US20090031440A1 (en) 2005-02-26 2009-01-29 Basf Plant Science Gmbh Expression Cassettes for Seed-Preferential Expression in Plants
EP2444496A1 (fr) 2005-04-15 2012-04-25 Del Monte Fresh Produce Company Promoteurs végétaux, terminateurs, gènes, vecteurs et plantes transformées associées
ATE552343T1 (de) 2005-04-19 2012-04-15 Basf Plant Science Gmbh Endosperm-spezifische expression und/oder expression in keimenden embryos monokotyledoner pflanzen
EP1882037A2 (fr) 2005-05-10 2008-01-30 BASF Plant Science GmbH Cassettes d'expression pour l'expression préferentielle de semence dans des plantes
EP1896575B1 (fr) 2005-06-17 2012-07-18 BASF Plant Science GmbH Polypeptides liés au stress du type lectine d'une protéine kinase et ses méthodes d'utilisation dans des plantes
EP1904521B1 (fr) 2005-07-08 2013-08-21 Universidad Nacional Autonoma De Mexico Instituto Nouvelles proteines bacteriennes avec activite pesticide
CN101228277B (zh) 2005-07-18 2013-11-27 巴斯福植物科学有限公司 过表达accdp基因的植物中的产量增加
WO2007011736A2 (fr) 2005-07-18 2007-01-25 Basf Plant Science Gmbh Augmentation du rendement dans des plantes surexprimant les genes shsrp
EP1915452A2 (fr) 2005-08-12 2008-04-30 BASF Plant Science GmbH Sequences d'acides nucleiques codant des proteines associees a la reponse au stress abiotique, cellules vegetales et vegetaux presentant une tolerance amelioree au stress environnemental
US7622573B2 (en) 2006-01-17 2009-11-24 Biolex, Inc. Expression control elements from the lemnaceae family
EP2343375A3 (fr) 2006-03-24 2012-02-08 BASF Plant Science GmbH Protéines associées à une réponse au stress abiotique et homologues
BRPI0808008B1 (pt) 2007-02-16 2016-08-09 Basf Plant Science Gmbh molécula de ácido nucleico isolada, cassete de expressão, vetor de expressão, métodos para excisão de sequências alvo de uma planta, para produzir uma planta com rendimento aumentado, e/ou tolerância a estresse aumentada, e/ou qualidade nutritional aumentada, e/ou teor de óleo aumentado ou modificado de uma semente ou broto para a planta, e, uso da molécula de ácido nucleico
US8329991B2 (en) 2007-03-23 2012-12-11 Basf Plant Science Gmbh Transgenic plant with increased stress tolerance and yield
CN101679999A (zh) 2007-05-29 2010-03-24 巴斯福植物科学有限公司 具有增加的胁迫耐受性和产率的转基因植物
WO2009010460A2 (fr) 2007-07-13 2009-01-22 Basf Plant Science Gmbh Plantes transgéniques présentant une tolérance au stress accrue et un rendement accru
EP2183373A2 (fr) 2007-08-02 2010-05-12 BASF Plant Science GmbH Plantes transgeniques a rendement et tolerance au stress accrus
CN101889089B (zh) 2007-11-27 2013-10-23 巴斯夫植物科学有限公司 具有增加的胁迫耐受性和产率的转基因植物
EP2329027A1 (fr) 2008-08-20 2011-06-08 BASF Plant Science GmbH Plantes transgéniques renfermant une phosphatidate cytidylyltransférase comme transgène
CA2737526A1 (fr) 2008-09-23 2010-04-01 Basf Plant Science Gmbh Plantes transgeniques avec un rendement accru
EP3168307B1 (fr) 2008-11-28 2020-07-15 Boehringer Ingelheim Animal Health USA Inc. Vaccin contre la grippe aviaire recombiné et ses utilisations
US8293533B2 (en) 2008-12-19 2012-10-23 E.I. Du Pont De Nemours And Company Site-specific integration and stacking of transgenes in soybean via DNA recombinase mediated cassette exchange
DE112010000693T5 (de) 2009-01-28 2012-11-22 Basf Plant Science Company Gmbh Transgene Pflanzen mit verändertem Stickstoffmetabolismus
EP2391721A2 (fr) 2009-01-28 2011-12-07 BASF Plant Science Company GmbH Manipulation des facteurs de transcription nf-yb pour augmenter la résistance à la sécheresse et le rendement de végétaux transgéniques
EP2411524A1 (fr) 2009-03-23 2012-02-01 BASF Plant Science Company GmbH Plantes transgéniques présentant des mécanismes redox modifiés et un rendement accru
EP2435562A1 (fr) 2009-05-26 2012-04-04 Biolex Therapeutics, Inc. Compositions et procédés permettant la production de plasminogène aglycosylé
EP2451958A1 (fr) 2009-07-10 2012-05-16 BASF Plant Science Company GmbH Cassettes d'expression pour l'expression spécifiquement dans l'endosperme dans des plantes
WO2011008096A1 (fr) 2009-07-16 2011-01-20 Wageningen Universiteit Régulation d'une déficience en zinc et d'une tolérance au zinc dans des plantes
AU2010325720A1 (en) 2009-12-03 2012-07-19 Basf Plant Science Company Gmbh Expression cassettes for embryo-specific expression in plants
US20130055471A1 (en) 2009-12-15 2013-02-28 Edwin Henricus Antonius HOLMAN Transgenic Ozone-Resistant Plants
JP5933451B2 (ja) 2009-12-28 2016-06-08 メリアル リミテッド 組換えｎｄｖ抗原及びその使用
CA2792117C (fr) 2010-03-12 2016-09-20 Merial Limited Vaccins de recombinaison contre le virus de la fievre aphteuse et utilisations de ceux-ci
CA2831144A1 (fr) 2011-03-23 2012-09-27 Pioneer Hi-Bred International, Inc. Procedes de production d'un locus complexe de caracteristique transgenique
WO2012174139A2 (fr) 2011-06-14 2012-12-20 Synthon Biopharmaceuticals B.V. Compositions et procédés pour la fabrication et l'utilisation de plantes transgéniques auxotrophes bioconfinées
EP2809787B8 (fr) 2012-02-02 2018-11-28 Consejo Nacional de Investigaciones Cientificas y Técnicas (CONICET) Hahb11 améliorant le rendement végétal et la tolérance au stress abiotique
WO2013136274A1 (fr) 2012-03-13 2013-09-19 University Of Guelph Promoteur myb55 et son utilisation
CA2875055A1 (fr) 2012-06-07 2013-12-12 Dow Agrosciences Llc Construction et procede d'expression de transgenes au moyen d'un promoteur constitutif bidirectionnel de brassica
WO2014018512A1 (fr) 2012-07-26 2014-01-30 Dow Agrosciences Llc Assemblage de fragments d'adn à rendement élevé
JP2015524672A (ja) 2012-08-17 2015-08-27 ダウ アグロサイエンシィズ エルエルシー 植物における導入遺伝子発現のためのトウモロコシ非翻訳領域の使用
US20140123339A1 (en) 2012-10-31 2014-05-01 Pioneer Hi Bred International Inc Transformed Plants Having Increased Beta-Carotene Levels, Increased Half-Life and Bioavailability and Methods of Producing Such
US20140203176A1 (en) 2013-01-23 2014-07-24 Dow Agrosciences Llc Systems and methods for real-time sampling and analysis of biomolecules beneath the surface of biological tissue
EP3010939A2 (fr) 2013-06-17 2016-04-27 Asana BioSciences, LLC Molécule d'immunofusion ciblant 5t4 et procédés correspondants
RU2017112324A (ru) 2014-09-12 2018-10-15 Пайонир Хай-Бред Интернэшнл, Инк. Создание сайтов сайт-специфической интеграции для сложных локусов признаков в кукурузе и сое, а также способы применения
EP3115458A1 (fr) 2015-07-06 2017-01-11 Genective Procédé d'optimisation de gène
WO2017083092A1 (fr) 2015-11-10 2017-05-18 Dow Agrosciences Llc Procédés et systèmes de prédiction de silençage transgénique
BR112018072473A2 (pt) 2016-05-20 2019-02-19 Basf Agro Bv molécula de ácido nucleico, cassete de expressão, célula vegetal, planta, semente, métodos para expressar um ácido nucleico, produzir uma planta, controlar vegetação e cultivar a planta, combinação útil para o controle, processo para preparar uma combinação e uso de uma combinação
WO2019133371A1 (fr) 2017-12-27 2019-07-04 Pioneer Hi-Bred International, Inc. Transformation de plantes dicotylédones
WO2020005933A1 (fr) 2018-06-28 2020-01-02 Pioneer Hi-Bred International, Inc. Procédés de sélection de plantes transformées
EP3874050A1 (fr) 2018-10-31 2021-09-08 Pioneer Hi-Bred International, Inc. Compositions et procédés de transformation de plante médiée par ochrobactrum
CN113412333A (zh) 2019-03-11 2021-09-17 先锋国际良种公司 用于克隆植物生产的方法
WO2020198408A1 (fr) 2019-03-27 2020-10-01 Pioneer Hi-Bred International, Inc. Transformation d'explant de plante
US20220154193A1 (en) 2019-03-28 2022-05-19 Pioneer Hi-Bred International, Inc. Modified agrobacterium strains and use thereof for plant transformation
CN113939594A (zh) 2019-04-18 2022-01-14 先锋国际良种公司 用于植物细胞的细胞重编程的胚发生因子
WO2021183803A1 (fr) 2020-03-11 2021-09-16 BASF Agricultural Solutions Seed US LLC Séquences nucléotidiques régulant la transcription et procédés d'utilisation
EP4222165A2 (fr) 2020-09-30 2023-08-09 Pioneer Hi-Bred International, Inc. Transformation rapide d'explants de feuilles de monocotylédone
EP4231816A1 (fr) 2020-10-21 2023-08-30 Pioneer Hi-Bred International, Inc. Facteurs de parthénogenèse et leurs procédés d'utilisation
EP4232586A1 (fr) 2020-10-21 2023-08-30 Pioneer Hi-Bred International, Inc. Inducteur haploïde doublé
WO2023183918A1 (fr) 2022-03-25 2023-09-28 Pioneer Hi-Bred International, Inc. Procédés d'induction d'haploïdes parthénogénétiques et de doublement de chromosomes haploïdes
WO2024099765A2 (fr) 2022-11-10 2024-05-16 BASF Agricultural Solutions Seed US LLC Séquences nucléotidiques régulant la transcription et procédés d'utilisation

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH02500566A (ja) * 1987-08-17 1990-03-01 プラント・ジェネティック・システムズ・エヌ・ブイ バチルス・スリンギエンシスからのｄｎａ配列で形質転換された植物
NZ230375A (en) * 1988-09-09 1991-07-26 Lubrizol Genetics Inc Synthetic gene encoding b. thuringiensis insecticidal protein
ES2164633T3 (es) * 1989-02-24 2002-03-01 Monsanto Technology Llc Genes vegetales sinteticos y procedimiento para su preparacion.

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See references of WO9116432A1 *

Also Published As

Publication number Publication date
AU651101B2 (en) 1994-07-14
JPH05506578A (ja) 1993-09-30
AU7695391A (en) 1991-11-11
CA2080584C (fr) 2000-09-05
WO1991016432A1 (fr) 1991-10-31
CA2080584A1 (fr) 1991-10-19

Similar Documents

Publication Publication Date Title
AU651101B2 (en) Modified bacillus thuringiensis insecticidal-crystal protein genes and their expression in plant cells
CA1341428C (fr) Gene d'une proteine cristalline insecticide synthetique
EP0861021B1 (fr) Gene modifie de bacillus thuringiensis pour combattre les lepidopteres sur les plantes
EP1127125B1 (fr) Procedes servant a transformer des plantes pour exprimer les delta-endotoxines du bacille thuringiensis
US6015891A (en) Synthetic insecticidal crystal protein gene having a modified frequency of codon usage
US5349124A (en) Insect-resistant lettuce plants
US5380831A (en) Synthetic insecticidal crystal protein gene
EP0358557B1 (fr) Plantes transformées par une séquence d'ADN, lethale pour les lepidoptera, de bacillus thuringiensis
US5567600A (en) Synthetic insecticidal crystal protein gene
AU677956B2 (en) New bacillus thuringiensis strains and their insecticidal proteins
Sutton et al. Synthetic cryIIIA gene from Bacillus thuringiensis improved for high expression in plants
US5877306A (en) Modified Bacillus thuringiensis insecticidal-crystal protein genes and their expression in plant cells
JPH07500966A (ja) 修飾遺伝子及びそれらの植物細胞における発現
Chan et al. Expression of Bacillus thuringiensis (Bt) insecticidal crystal protein gene in transgenic potato
Diehn Bt toxin gene expression and differential utilization of polyadenylation signals in gramineous and dicotyledonous plants
MXPA98002778A (en) Gene of bacillus thuringiensis modified for control of lepidopteros in plan

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 19920928

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE CH DE DK ES FR GB GR IT LI LU NL SE

17Q First examination report despatched

Effective date: 19941230

RAP1 Party data changed (applicant data changed or rights of an application transferred)

Owner name: AVENTIS CROPSCIENCE N.V.

RAP1 Party data changed (applicant data changed or rights of an application transferred)

Owner name: AVENTIS CROPSCIENCE N.V.

GRAG Despatch of communication of intention to grant

Free format text: ORIGINAL CODE: EPIDOS AGRA

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION HAS BEEN REFUSED

18R Application refused

Effective date: 20020725